Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|October 29, 2020
Implementing Risk-based Monitoring in Oncology Trials Sharing case studies and insights on the impact to study quality and patient safety
Author(s)IQVIA
***Live: Thursday November 12, 2020 at 11am EST***Oncology trials of various types and phases present unique challenges for effectively conducting trials, and firms are implementing risk-based monitoring (RBM) practices to improve quality and patient safety.***On demand available after final airing until Nov. 12, 2021***
Register Free:
Event Overview: Clinical research & development is at a crossroads, requiring new approaches to deliver drugs to market faster – with less cost – while mitigating risk, and without compromising safety or quality. The market is moving towards risk-based monitoring (RBM) to monitor clinical trials as it provides new levels of efficiency and quality while providing predictability of speed and operational outcomes.
Key Learning Objectives:
- The industry continues to change, and risk-based monitoring (RBM) is helping pharmaceutical firms improve the efficiency, quality and safety of their oncology trials to bring new therapies to patients faster
- RBM is using advanced technologies, including AI, ML, and predictive analytics to provide new levels of insights to mitigate risks while improving quality and patient safety
- Oncology trials are an industry leader in the adoption of RBM practices for their clinical trials – understand why with case studies and lessons learned from this webinar
Speakers: Zabir Macci, Centralized Monitoring Manager, Clinical Operations Process Design,Analytics, IQVIA
Susana Nolley, MPH,mDirector, Clinical Project Management, Oncology Project Leadership, IQVIA
Time and Date: Thursday November 12, 2020 at 11am EST
On demand until Nov. 12 2021.
Sponsor: IQVIA
Register Free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5